Results for tag: "Antiphospholipid Syndrome"

Antiphospholipid Syndrome (APS) is a rare autoimmune disorder characterized by the presence of antiphospholipid antibodies in the blood. These antibodies can cause recurrent thrombosis, pregnancy complications, and other organ damage. APS is a major cause of morbidity and mortality in patients with hematological disorders, such as thrombocytopenia, hemolytic anemia, and thrombotic thrombocytopenic purpura. Treatment of APS involves anticoagulant therapy, such as warfarin, and immunosuppressive drugs, such as hydroxychloroquine. The APS market is a growing segment of the hematology market, with a focus on the development of novel therapies to improve patient outcomes. Companies in this market are developing new drugs and biologics to target the underlying cause of APS, as well as new diagnostics to identify patients at risk. Examples of companies in this market include AbbVie, AstraZeneca, Bristol-Myers Squibb, and Pfizer. Show Less Read more